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Increased and sustained expression of p-Akt in HCC827 cells with 
the acquired resistance to gefitinib
Lee, Jae Cheol; Choi, Yun Jung; Rho, Jin Kyung; Na, Im Il; 
Ryoo, Bae-Yeol; Lee, Jin Kyung; Yang, Sung Hyun; Kim, Cheol Hyeon 
Korea Cancer Center Hospital, Seoul, Korea
Geﬁtinib, a speciﬁc inhibitor of epidermal growth factor receptor 
tyrosine kinase (EGFR-TK), has shown promising activity in lung 
cancer. However, tumor cells eventually acquire the resistance limiting 
duration of efﬁcacy. To characterize lung cancer cells with the acquired 
resistance to geﬁtinib, a resistant subline HCC827/GR was established 
by repeated exposure to the drug for more than 6 months. Compared 
with parent HCC827 cells having delE746-A750 mutation, HCC827/
GR cells were 5676.8-fold more resistant to geﬁtinib and showed the 
cross-resistance against erlotinib and cetuximab. However, the resis-
tance to other chemotherapeutic drugs such as CL-387,785, ZD6474, 
cisplatin, etoposide, gemcitabine and paclitaxel, developed to a lesser 
degree suggesting that they would have more favorable response. 
Several factors related with the sensitivity to geﬁtinib were evaluated. 
The secondary mutation of T790M was not detected by sequencing 
and EGFR gene copy number by FISH was not changed. In addition, 
the epithelial-to-mesenchymal transition was not found. However, 
the expression of p-Akt was markedly increased and not reduced by 
treatment with geﬁtinib. The redundant pathways to activate Akt other 
than EGFR might develop and exert an important role in the acquired 
resistance to geﬁtinib. 
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To overcome T790M associated EGFR TKI resistance by addition 
of mono-clonal antibodies against HER-1 and/or HER-2 receptors 
Mok, Tony S.; Choi, Eve; Wong, Cesar; Leung, Linda; Lui, Philip; To, 
Kai Fai; Lam, Kwok Chi; Lui, Vivian 
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Background: Almost all NSCLC that attained disease control on 
EGFR TKI would eventually become resistant. About 50% of cases 
are associated with secondary mutation in EGFR (e.g. T790M at exon 
20). Previously, Cetuximab alone (an EGFR monoclonal antibody), 
has been shown to induce growth inhibition of a geﬁtinib-resistant 
NSCLC line harboring T790M. Here, we attempt to overcome geﬁtinib 
resistance by combined targeting of geﬁtinib with HER-1 (EGFR) 
and HER-2 with monoclonal antibodies cetuximab and trastuzumab, 
respectively. We hypothesize that combination of monoclonal antibod-
ies with geﬁtinib may elicit synergistic antitumor activity in geﬁtinib-
resistant NSCLC cell line.
Methods: NSCLC Cell lines: NCI-H1650 (DelE746A750) is geﬁtinib-
sensitive, and NCI-H1975 (L858R, T790M) is geﬁtinib-resistant. Cells 
were treated with respective drug alone or in combination for 72h. 
Growth inhibition was evaluated by MTT assay. Effect of combination 
treatment on EGF-induced phosphorylation of Akt and MAPK was 
determined by Western blotting. 
Results: Percentage of cell kill by combined treatment of cetuximab 
and geﬁtinib on NCI-H1975 (geﬁtinib-resistant) was superior to 
geﬁtinib alone, and the combination was able to restore to level similar 
to geﬁtinib alone on the sensitive cell line (NCI-H1650). However, ad-
dition of cetuximab was only mildly synergistic on NCI-H1975 (~30% 
enhanced cell kill over the theoretical additive cell kill of the two 
agents alone). We demonstrated that the geﬁtinib/cetuximab combina-
tion, but not geﬁtinib alone, was able to down-regulate EGF-induced 
phosphorylation of Akt and MAPK in NCI-H1975 in a dose-dependent 
manner (Figure 1). Addition of trastuzumab could further increase cell 
kill of the geﬁtinib/cetuximab combination on NCI-H1975 cell lines. 
Keeping concentration of cetuximab at 0.5ug/ml and geﬁtinib at 10uM 
we found the synergism (over three agents alone) with addition of 
trastuzumab being most pronounced at lower dose (Table 1).
Conclusion: T790M associated EGFR TKI resistance is potentially 
reversible. Addition of cetuximab with or without trastuzumab restore 
cell kill in resistant cell line. 
Trastuzumab conc Theoretical Cell Kill Experimental Cell Kill
Increase in %  
of Cell Kill
0.5 13.9 27.1 95%
0.1 7.2 26.2 263%
0.01 9.9 25.6 158%
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Background: The multitargeted antifolate (pemetrexed disodium; Al-
imta) is indicated for the treatment of patients with locally advanced or 
metastatic NSCLC after prior chemotherapy as a single-agent, and with 
malignant pleural mesothelioma in combination with platinum. We 
have investigated putative biomarker genes of pemetrexed sensitivity 
with SCLC and NSCLC cell lines. 
Materials and Methods: Nine different lung cancer cell lines were 
used: squamous (H157), adenocarcinoma (A549, H1648, H2122, and 
H1975), bronchioalveolar carcinoma (H358), and extensive stage small 
cell carcinoma (H69, H526, and H748). These cells were grown at 
37˚C in humid atmosphere containing 5% CO
2
 in RPMI-1640 medium 
supplemented with 10% fetal bovine serum. All cell counts were made 
with a hematocytometer using trypan blue exclusion to distinguish 
between live and dead cells. NSCLC cells were seeded at 1-2*104 /ml, 
and SCLC cells were seeded at 1-2*105 /ml in 96-well plates (100μl/
well). They were incubated at 37˚C for 16-24 hours prior to pemetrexed 
treatment. Drug or control medium (100μl/well) were added at the 
incubated concentration, and proliferation was assessed for all cell lines 
over a 6-day time course. MTT 50μl was added to each well, and plates 
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were incubated at 37˚C for 4 hours. A reading of each well was done 
using the MAXline Microplate Readers to evaluate pemetrexed IC50 
value. Microarray analysis was performed with Affymetrix U-133 A&B 
and plus2 chips to detect putative biomarker genes which predict peme-
trexed sensitivity. Data analysis with obtained chip data was made with 
GeneSpring software. The relative ﬂuorescent intensity by microarray 
was validated by RT-PCR on the putative gene, Synovial Sarcoma X3 
(SSX3). 
Results: Three NSCLC cell lines (H157, A549 and H1648) had over 
100 nM/L IC50 value (high IC50), and remainder NSCLC cell lines 
(H2122, H1975 and H358) had under 20 nM/L (low IC50). In Gene-
Spring analysis, 12 genes which were 5 fold higher in sensitive cell 
lines than in resistant cell lines were chosen. As SCLC cell lines are 
usually ﬂoating and difﬁcult to select resistant cell lines, 3 cell lines 
were selected as sensitive lines with low IC50 values (18-34 nM/L). 
Then 3 genes out of 12 genes were selected which were compatible in 3 
sensitive SCLC cell lines. They were Slit 2, SSX3 and EST. Sense and 
antisense primers were made for RT-PCR, and SSX3 microarray results 
were validated with those. 
Conclusion: These results need to be veriﬁed in samples from clinical 
cohorts, which are NSCLC, SCLC and malignant pleural mesothelio-
ma. It was suggested that SSX3 would predict the pemetrexed sensitiv-
ity and extend the indications of that treatment.
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Activity of epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) in chemotherapy-pretreated non-small 
cell lung cancer (NSCLC) patients (pts) prospectively selected 
according to specific molecular predictive factors 
Nuzzo, Carmen 
Istituto Regina Elena, San Felice a Cancello, Italy
Background: EGFR TKIs are effective in a small proportion of chemo-
therapy-pretreated NSCLC pts. A number of molecular alterations along 
the EGFR pathway have been proposed as predictors of response to 
EGFR TKIs, but to date none of them has been prospectively validated.
Methods: Advanced, chemotherapy-pretreated, NSCLC pts were 
screened for the following EGFR pathway alterations: EGFR gene 
mutations (by SSCP and sequencing) and/or increased copy number 
(by FISH), EGFR protein expression (by IHC), and HER-2, phosphory-
lated AKT (pAKT), and total AKT protein expression (by IHC). Upon 
progression, pts were then assigned to treatment with an EGFR TKI 
(Iressa™ or Tarceva™) according to one of the following groups: A) 
mutated (regardless of any other parameter); B) non-mutated, ampliﬁed 
(either true gene ampliﬁcation or high-grade polysomy in > 40% of 
the tumor cells); C) non-mutated, non-ampliﬁed, EGFR positive (IHC 
score ≥ 1+); D) Adk or BAC histology and no smoking history (non-
mutated, non-ampliﬁed, EGFR-negative pts or unknown EGFR status).
Results: From January 2005, 129 pts were screened for EGFR pathway 
alterations, while undergoing chemotherapy. Thirteen pts were identi-
ﬁed in group A (6 with exon 19 deletions, 6 with exon 21 point muta-
tions, 1 with both); 39 pts in group B (including 7 pts with true gene 
ampliﬁcation); 32 pts in group C (including 19 pts with a pAKT IHC 
score ≥ 1+); 7 pts in group D (including 2 pts with BAC histology). 
Treatment results in the different subgroups are reported in Table 1. 
A B C D
N. treated 11 25 25 5
PR 2 2 1 1
SD ≥ 6 mos 2 5 4 0
SD < 6 mos 2 5 4 2
PD 4 9 15 1
Too Early 1 4 1 1
Awaiting treatment 2 14 7 2
 
Conclusions: Based on the data available so far, there seems to be a 
continuum of response/ disease control rate that progressively declines 
from group A to group C. Accrual to the study will be continued in all 
4 subgroups until computer simulations using a continual reassessment 
method will allow to conﬁdently exclude a true response rate ≥ 10% in 
any of the groups.
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Background: The cytochrome P450 (CYP) is associated with tumor 
development and progression as well as activation of anti-cancer pro-
drugs and their metabolic clearance. Recently, some CYPs, in particular 
enzymes of the CYP3A subfamily (CYP3A4, CYP3A5, and CYP3A7), 
have been found to play a role in the metabolism of many anticancer 
drugs. CYP3A not only inactivates major anticancer drugs, such as 
tamoxifen, taxol and vinca alkaloids, but also activates major anti-
cancer prodrugs, such as cyclophosphamide and ifosphamide. For the 
better management of lung cancer, it is essential to understand the roles 
of CYPs and the relationships between their expression and the clinical 
feature of individual lung cancers. In this study, we investigate the ex-
pression of four CYPs (CYP1A1, CYP2A6, CYP2E1 and CYP3A) in 
78 non-small cell lung cancer (NSCLC) and their relationships to each 
other, tumor p53 expression, and clinical features of the patients. 
Materials and Methods: We examined CYPs and p53 immunoreac-
tivities in 78 Japanese patients with NSCLC who underwent surgical 
resection at UOEH after obtaining appropriate informed consent. His-
tological typing of the tumors was performed according to the WHO 
classiﬁcation (adenocarcinoma; 48 cases, squamous cell carcinoma; 
30 cases). Immunohistochemical staining (IHC) of 78 NSCLC was 
performed by the LSAB (labelled streptavidine biotin) method. CYPs 
and p53 expression was determined as positive when more than 10% 
of tumor cells were stained. The p53 mutations in 48 adenocarcinomas 
were sequenced by the dideoxy chain termination method using an ABI 
373A DNA Sequencer (Applied Biosystems). 
Results: The CYP1A1, CYP2A6, CYP2E1 and CYP3A positive rates 
in 48 adenocarcinomas were 43.8% (21/48), 45.8% (22/48), 39.6% 
